Landiobloc

Landiolol Hydrochloride, the active ingredient in Landiobloc, is a beta‑blocker (ultra‑short‑acting, cardioselective) presented as an intravenous solution for intravenous use. It provides rapid rate control in tachyarrhythmias such as atrial fibrillation with rapid ventricular response, supraventricular tachycardia, and intra‑operative or peri‑operative tachycardia.

GNH USA supplies Landiobloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Landiolol Hydrochloride is a cardioselective beta‑blocker used to manage rapid heart rhythms. - Atrial fibrillation with rapid ventricular response: provides rapid heart‑rate reduction and rhythm stabilization. - Supraventricular tachycardia: achieves prompt control of ventricular rate. - Intra‑operative or peri‑operative tachycardia: enables immediate heart‑rate management during surgical procedures.

Landiolol Hydrochloride may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Bradycardia: excessive slowing of heart rate. - Hypotension: low blood pressure. - Dizziness: feeling light‑headed.

Serious or Rare Side Effects: - Severe bronchospasm: acute narrowing of airways. - Heart block: impairment of electrical conduction. - Allergic reaction: rash, itching, swelling.

When using Landiolol Hydrochloride, clinicians should observe several precautions to ensure patient safety. - Cardiovascular monitoring: continuous ECG and blood pressure assessment during infusion. - Dose adjustment: reduce dose in patients with pre‑existing severe heart failure. - Concomitant β‑blockers: avoid excessive β‑blockade by reviewing other β‑blocker therapy. - Respiratory caution: use cautiously in patients with asthma or chronic obstructive pulmonary disease. - Renal/hepatic impairment: monitor closely and adjust infusion rate if needed. - Store at room temperature: keep vials in original packaging, protect from light and moisture.

Landiolol Hydrochloride can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Calcium channel blockers (e.g., verapamil, diltiazem): may cause profound bradycardia or hypotension. - Other β‑blockers: additive negative chronotropic effects. - Digoxin: increased risk of heart block.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, ARBs): monitor blood pressure. - Anesthetic agents (e.g., propofol, volatile anesthetics): may enhance cardiovascular depression. - Diuretics: watch for electrolyte disturbances affecting cardiac conduction.